Marc Fishman1, Hoa T Vo, Rachael Burgower, Michael Ruggiero, John Rotrosen, Josh Lee, Edward Nunes. 1. Maryland Treatment Centers, Baltimore, MD (MF, RB, MR); Johns Hopkins University School of Medicine, Baltimore, MD (MF); University of Texas Southwestern Medical Center, Dallas, TX (HTV); New York University School of Medicine, New York, NY (JR, JL); New York State Psychiatric Institute, Columbia University Medical Center, New York, NY (EN).
Abstract
OBJECTIVES: The effectiveness of treatment incorporating relapse prevention medications for opioid use disorder (OUD) is typically examined in research using rigidly predefined endpoints of success versus failure, usually over a single episode of care. But this perspective may not adequately portray the nonlinear trajectories typical of real-world treatment courses in this chronic, remitting, and relapsing disorder. METHODS: This descriptive study examined 12-month treatment trajectories of n = 60 patients enrolled at a single site of a larger multisite randomized controlled trial examining the comparative effectiveness of buprenorphine versus extended-release naltrexone. While the parent study provided medication treatment through the research protocol for 6 months, this study documents treatment up to 12 months, including medications, provided through standard community resources (treatment as usual) outside of the protocol. RESULTS: Some patients continued medications past the end of the study intervention, whereas others did not. Some patients initiated medications other than the one assigned by the study. Some patients switched from 1 medication to the other. Many patients returned to treatment after 1 or more periods of dropout and/or relapse. Patients utilized multiple episodes of bed-based care, including short-term acute residential and long-term residential treatment, and also recovery housing supports. Described trajectories are also depicted graphically. At 12 months, while rates of continuous treatment retention were low (8%), rates of cross-sectional treatment engagement including return to treatment after drop out were higher (35%). CONCLUSIONS: This description of nonlinear treatment trajectories highlights the potential benefits of flexibility and optimism in the promotion of re-engagement, despite interim outcomes that might traditionally be considered "failure" endpoints.
RCT Entities:
OBJECTIVES: The effectiveness of treatment incorporating relapse prevention medications for opioid use disorder (OUD) is typically examined in research using rigidly predefined endpoints of success versus failure, usually over a single episode of care. But this perspective may not adequately portray the nonlinear trajectories typical of real-world treatment courses in this chronic, remitting, and relapsing disorder. METHODS: This descriptive study examined 12-month treatment trajectories of n = 60 patients enrolled at a single site of a larger multisite randomized controlled trial examining the comparative effectiveness of buprenorphine versus extended-release naltrexone. While the parent study provided medication treatment through the research protocol for 6 months, this study documents treatment up to 12 months, including medications, provided through standard community resources (treatment as usual) outside of the protocol. RESULTS: Some patients continued medications past the end of the study intervention, whereas others did not. Some patients initiated medications other than the one assigned by the study. Some patients switched from 1 medication to the other. Many patients returned to treatment after 1 or more periods of dropout and/or relapse. Patients utilized multiple episodes of bed-based care, including short-term acute residential and long-term residential treatment, and also recovery housing supports. Described trajectories are also depicted graphically. At 12 months, while rates of continuous treatment retention were low (8%), rates of cross-sectional treatment engagement including return to treatment after drop out were higher (35%). CONCLUSIONS: This description of nonlinear treatment trajectories highlights the potential benefits of flexibility and optimism in the promotion of re-engagement, despite interim outcomes that might traditionally be considered "failure" endpoints.
Authors: Diane Warden; Geetha A Subramaniam; Thomas Carmody; George E Woody; Abu Minhajuddin; Sabrina A Poole; Jennifer Potter; Marc Fishman; Michael Bogenschutz; Ashwin Patkar; Madhukar H Trivedi Journal: Addict Behav Date: 2012-05-08 Impact factor: 3.913
Authors: Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes Journal: Am J Psychiatry Date: 2017-01-10 Impact factor: 18.112
Authors: Charles Ruetsch; Joseph Tkacz; Vijay R Nadipelli; Brenna L Brady; Naoko Ronquest; Hyong Un; Joseph Volpicelli Journal: Am J Manag Care Date: 2017-06-01 Impact factor: 2.229
Authors: Yih-Ing Hser; Elizabeth Evans; David Huang; Robert Weiss; Andrew Saxon; Kathleen M Carroll; George Woody; David Liu; Paul Wakim; Abigail G Matthews; Mary Hatch-Maillette; Eve Jelstrom; Katharina Wiest; Paul McLaughlin; Walter Ling Journal: Addiction Date: 2016-01-13 Impact factor: 6.526
Authors: Edward V Nunes; Joshua D Lee; Dominic Sisti; Andrea Segal; Arthur Caplan; Marc Fishman; Genie Bailey; Gregory Brigham; Patricia Novo; Sarah Farkas; John Rotrosen Journal: Contemp Clin Trials Date: 2016-09-28 Impact factor: 2.226
Authors: Joshua D Lee; Edward V Nunes; Patricia Novo; Ken Bachrach; Genie L Bailey; Snehal Bhatt; Sarah Farkas; Marc Fishman; Phoebe Gauthier; Candace C Hodgkins; Jacquie King; Robert Lindblad; David Liu; Abigail G Matthews; Jeanine May; K Michelle Peavy; Stephen Ross; Dagmar Salazar; Paul Schkolnik; Dikla Shmueli-Blumberg; Don Stablein; Geetha Subramaniam; John Rotrosen Journal: Lancet Date: 2017-11-14 Impact factor: 79.321
Authors: Jennifer S Potter; Elise N Marino; Maureen P Hillhouse; Suzanne Nielsen; Katharina Wiest; Catherine P Canamar; Judith A Martin; Alfonso Ang; Rachael Baker; Andrew J Saxon; Walter Ling Journal: J Stud Alcohol Drugs Date: 2013-07 Impact factor: 2.582
Authors: Dana Button; Ryan Cook; Caroline King; Tong Thi Khuyen; Lynn Kunkel; Gavin Bart; Dinh Thanh Thuy; Diep Bich Nguyen; Christopher K Blazes; Le Minh Giang; P Todd Korthuis Journal: Int J Drug Policy Date: 2021-11-09
Authors: Miranda G Greiner; Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Patricia Novo; Marc Fishman; Joshua D Lee; John Rotrosen; Edward V Nunes Journal: J Subst Abuse Treat Date: 2021-04-30